Xueliang Wang, Xueliang Wang, Zhe Wang, Di Liu, Hao Jiang, Hao Jiang, . . . Guangli Yu. (2022). Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Frontiers Media S.A..
Chicago Style (17th ed.) CitationXueliang Wang, et al. Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Frontiers Media S.A., 2022.
MLA (9th ed.) CitationXueliang Wang, et al. Canagliflozin Prevents Lipid Accumulation, Mitochondrial Dysfunction, and Gut Microbiota Dysbiosis in Mice With Diabetic Cardiovascular Disease. Frontiers Media S.A., 2022.
Warning: These citations may not always be 100% accurate.